In Brief: St. Jude/Cyberonics
This article was originally published in The Gray Sheet
St. Jude/Cyberonics: Merger agreement cleared by Cyberonics shareholders, the firm announces July 23. The action gives St. Jude until October 18 to exercise its option to complete a $72 mil. merger transaction under an April 8 agreement -- time to evaluate results from a second clinical trial of Cyberonics' NCP (NeuroCybernetic Prosthesis) neurological stimulation device ("The Gray Sheet" April 15, I&W-3). Cyberonics also completes the sale of 2.2 mil. new shares of common stock to St. Jude at $5.50 each for an aggregate of $12 mil. -- the merger agreement called for the equity financing upon Cyberonics shareholder approval...
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.